2013 acr/arhp annual meeting session · manage your meeting your way with my annual meeting my...

P r e–m e e t i n g Co u rs es: o c to b e r 25–26, 2013

o P e n i n g l eC t u r e a n d awa r d s: o c to b e r 26, 2013

s C i e n t i f i C s es s i o n s: o c to b e r 26–30, 2013

2 0 1 3 A C R / A R H P A N N U A L M E E T I N G

sessionT R A C K E R

Manage Your Meeting Your Way with My Annual Meeting

My Annual Meeting is an online tool created to help you navigate the ACR/ARHP Annual Meeting using your laptop or tablet.

Start by browsing the program in Meeting at a Glance or view abstracts in the Abstracts section, or login* to build your schedule.

*�To�login,�use�the�ACR�ID—found�on�your�registration�confirmation�or�name�badge—and�your�last�name.

Visit MyAnnualMeeting.org to:

Search for sessions or abstracts

Add sessions to your schedule

Enter/claim CME credits

View session syllabi

See which sessions will be available on SessionSelect

Export your schedule to your smartphone

Questions? Visit the Technology Center in the Sails Pavilion.

3

session t r a C K e r

U se the Session tracker to record your cMe/Hours of Participation as you go, then use the Session tracker as a guide to apply for cMe/Hours of Participation online in My Annual Meeting at www.aCrannualmeeting.org to obtain a certificate for your records.

Educational TracksLook for these icons to navigate the meeting by track:

BASIC SCIENCE BUSINESS/ADMINISTRATION CLINICAL SCIENCE CLINICAL PRACTICE

PM PS PAIN MANAGEMENT PM PS PATIENT SAFETY

accreditation statement: the American college of rheumatology is accredited by the Accreditation council for continuing Medical education (AccMe) to provide continuing medical education for physicians.

designation statement: the Acr designates this live educational activity for a maximum of 51.75 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

international Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s)™, must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and e–mail address. the information will be used to verify your meeting attendance.

the American Medical Association has an agreement of mutual recognition of continuing medical education credit with the european Union of Medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit ™ to eAccMe credit should contact the UeMS.

Health Professionals: Participants may claim hours to receive a certificate of Participation for an activity designated for AMA PRA Category 1 Credit(s)™. For non–cMe sessions, attendees may also request a certificate of participation.

4


IMPORTANT LOCATIONS

aCr office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23A; telephone: (619) 525-6200

attendee lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall D Lobby

Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall F-G, Discovery center – booth 1421

Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . call for Location; telephone: (858) 254-2563

Clinical trial/registry Posters . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

Coat/Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Under Hall D escalator

Concierge Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

discovery Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, booth 1421

exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G

first aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .box office G

foundation Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall F-G, Discovery center - booth 1421

foundation donors’ lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . .24b-c

graffiti walls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion and exhibit Hall F-G

Hotel reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

industry-supported symposia information . . . . . . . . . . . . . . .Hall D Lobby

innovation theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, booth 731

lost and found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Acr office (23A)

membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26A-b; telephone: (619) 525-6204

nursing mothers’ room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7A

X


5

overflow rooms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25B 308 (Hilton San Diego bayfront)

Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall b2-c-D

Prayer room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21

recharge areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall F-G, Attendee Lounge (Sails Pavilion)

registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

restaurant reservations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall b Lobby and Sails Pavilion

ribbon distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Sails Pavilion)

SessionSelect lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall D Lobby (Monday – Wednesday)

shuttle Bus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall e Lobby

simple tasks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Halls F-G, Discovery center – booth 1421

speaker ready room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22

technology Center (Cme/internet) . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion

Visitor information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall b Lobby

wheelchairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . order through ScootAround, Inc.; telephone: (888) 441-7575. (The�San�Diego�Convention�Center� does not provide wheelchairs for general�use.)

wi-fi way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G

special needs If you require special arrangements, please contact the Acr office (23A); telephone: (619) 525-6200.

emergency Contact information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder.

Printing�of�this�publication�is�supported�by�Amgen,�Inc.

�—�denotes�Hilton�San�Diego�Bayfront�room�location6

Meeting At–A–Glance FRIDAY & SATURDAY, OCTOBER 25 – 26


FRIdAy, OCTObeR 25, 2013

Time Title Location CME/Hours of Participation

6:30 am – 6:00 pm

aCr/arHP registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sails Pavilion

Pre–meeting courses

7:45 am – 5:30 pm

aCr musculoskeletal ultrasound Course for rheumatologists – Day one of two . . . . . . . . . . . . . . . . . . . . . . .

16 A-b

8.25 hrs

9:00 am – 5:00 pm

aCr Certified rheumatology Coder Course: the Anatomy of rheumatology coding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32 A-b

1:00 – 6:00 pm

aCr Basic research Conference: beyond Germline Genetics: New Perspectives on rheumatic Disease Predisposition – Day one of two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 A

4.75 hrs

1:00 – 6:00 pm

aCr Clinical research Conference: Preclinical rheumatic Disease – Day one of two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 D

4.75 hrs

1:00 – 6:00 pm

aCr/aBim maintenance of Certification learning session – 2013 Update in rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . .

33 A

4.5 hrs

SATuRdAy, OCTObeR 26, 2013


6:30 am – 6:30 pm

aCr/arHP registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sails Pavilion

Pre-meeting courses

7:15 am –5:30 pm

aCr musculoskeletal ultrasound Course for rheumatologists – Day two of two . . . . . . . . . . . . . . . . . . . . . . .

16 A-b

8.75 hrs

7:30 am –4:30 pm

aCr Clinical research Conference: Preclinical rheumatic Disease – Day two of two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 D

7.75 hrs

8:00 am –4:00 pm

aCr review Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall b1 6.0 hrs

8:00 am –4:30 pm

aCr Basic research Conference: beyond Germline Genetics: New Perspectives on rheumatic Disease Predisposition – Day two of two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 A

7.25 hrs

�—�denotes�Hilton�San�Diego�Bayfront�room�location 7

SATURDAY & SUNDAY, OCTOBER 26 – 27 Meeting At–A–Glance


8:00 am –4:30 pm

arHP Clinical focus Course: Meeting the challenges of Measuring outcomes in rheumatology clinical Practice PM PS PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32 A-b

6.5 hrs

8:00 am –5:00 pm

aCr Practice management Pre-meeting Course PM PS . . . . 33 A 6.75 hrs

4:30 –6:15 pm

aCr/arHP opening lecture and awardsLife at the Speed of Light . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom 20 A

0.75 hrs

6:15 –7:30 pm

aCr/arHP Champagne reception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sails Pavilion

SuNdAy, OCTObeR 27, 2013


6:30 am – 6:00 pm


Sails Pavilion

7:30 – 8:30 am

aCr sessions Acr Pediatric rheumatology town Hall Meeting . . . . . . . . .

Adult onset Still’s Disease: A clinical review from Pathophysiology to therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year in review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 c ballroom 20 AHall b1

1 hr.

7:30 –9:00 am

aCr sessionsMacrophage Polarization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Patient engagement/Privacy and Security PM PS . . . . . . . . . . .

Indigo e28 D

1.5 hrs.

7:45 –8:30 am

arHP networking event First-time Attendee orientation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 A

7:45 –9:15 am

aCr meet the Professor sessions Antiphospholipid Syndrome (001) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

crystal: Diagnosis and Management of Gout (002) PM PS . . . . . .

Dermatological Manifestations of rheumatic Diseases (003) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatric Systemic Lupus erythematosus (004) . . . . . . . . . . . . . . . .

Pediatrics: Spondylarthritis in children (005) . . . . . . . . . . . . . . . . . .

Psoriatic Arthritis (006) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

rheumatoid Arthritis: challenging cases (007) . . . . . . . . . . . . . . . .

rheumatoid Arthritis: outcome Measures in clinical Practice (008) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Spondylarthropathy: An Update (009) . . . . . . . . . . . . . . . . . . . . . . . . .

Systemic Lupus erythematosus: Novel treatments (010) . . . . .

1213 14 A14 b15 A15 b16 A 16 b17 A17 b

1.5 hrs.

8

Meeting At-A-Glance SUNDAY, OCTOBER 27


�—�denotes�Hilton�San�Diego�Bayfront�room�location

7:45 –9:45 am

aCr workshops Histopathology of rheumatic Lung Disease (201) . . . . . . . . . . . . .

Magnetic resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A clinician's Guide (202) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Muscle Involvement in rheumatic Diseases (203) . . . . . . . . . . . .

1 A 41 b

2.0 hrs.

8:30 –9:00 am

arHP networking event Moderator orientation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 b

8:30 –10:00 am

aCr sessions Legislative Update from capitol Hill . . . . . . . . . . . . . . . . . . . . . . .

Medical education: the Year in review . . . . . . . . . . . . . . . . . . .

Where’s the Money? A comprehensive Approach to Funding Your Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

306 A Sapphire A

202 A

1.5 hrs.

1.5 hrs.

8:30 am –4:00 pm

aCr Poster session a and Poster tours . . . . . . . . . . . . . . . . . . . . . .Abstracts (#1–760)

Poster Hall Morning Snack break (8:30 – 10:00 am)

Poster Presenters available9:00 – 11:00 am

guided Poster tours9:00 – 9:45 am301 – Fellows only: How to Navigate the Poster Hall 302 – Pediatric rheumatology: clinical Aspects Poster tour 303 – rheumatoid Arthritis treatment: Small Molecules,

biologics and Gene therapy Poster tour304 – Rheumatology�Research�Foundation Poster tour:

Innate Immunity 305 – Spondylarthropathies and Psoriatic Arthritis: clinical

Aspects and treatment Poster tour 306 – Systemic Lupus erythematosus: clinical Aspects

Poster Tour

10:15 – 11:00 am307 – epidemiology and Health services research

Poster Tour308 – Genetics, Genomics and Proteomics Poster tour 309 – rheumatoid Arthritis treatment - Small Molecules,

biologics and Gene therapy Poster tour 310 – rheumatoid Arthritis: clinical Aspects Poster tour 311 – Spondylarthropathies and Psoriatic Arthritis: clinical

Aspects and treatment Poster tour 312 – Systemic Lupus erythematosus: clinical Aspects

Poster Tour

Poster Hall (exhibit Hall b2-c-D)

2.0 hrs.


9

SUNDAY, OCTOBER 27 Meeting At-A-Glance



9:00 –10:00 am

aCr sessions corc ForUM: Disaster Planning: How to Prepare for a catastrophe and Minimize your Liability . . . . . . . . . . . . . . . .

Inflammation and Atherosclerosis: Autoimmunity and cardiovascular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

New therapies for Modulating cell Signaling in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Rheumatology�Research�Foundation Memorial Lecture: Pediatric rheumatology – Where We’ve been, Where We’re Going . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Rheumatology�Research�Foundation oscar S. Gluck, MD, Memorial Lectureship: the contribution of bone to Whole organism Physiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

the Link between Inflammation in the Joint and the Gut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Update on thrombotic Microangiopathies . . . . . . . . . . . . . . . .

Sapphire I

6 D ballroom 20 A 6 c 6 A 30 eHall b1

1.0 hr.

9:00 –10:00 am

arHP sessionKeynote Address: Words that Heal . . . . . . . . . . . . . . . . . . . . . . . . 29 D

1.0 hr.

10:00 am –5:00 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall Morning Snack break (10:00 – 11:00 am)exhibit Hall Afternoon Snack break (2:00 – 3:00 pm)

exhibit HallF-G

10:30 –11:15 am

innovation theaterSee�page�31�for�the�Innovation�Theater�Listing . . . . . . . . . . . . . . . .

exhibit Hall F-G (booth #731)

10:30 am –12:30 pm

aCr workshops Advanced Musculoskeletal Ultrasound (204) . . . . . . . . . . . . . . . . . .

basic Statistical concepts for the Medical researcher (205) . .

Dermatopathology of rheumatic Diseases (206) . . . . . . . . . . . . . .

Peripheral Magnetic resonance Imaging in rheumatology Practice (207) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Physical examination Skills for Improved Detection of Synovitis and cervical thoracolumbar Disorders (208). . . . . . . .

41 b1 A 3 2

2.0 hrs.

11:00 am –Noon

arHP sessions Health Literacy Universal Precautions for the rheumatology Setting PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Immunology boot camp Session 1: the basics of targeted therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Mediation Analysis: theory and Method for causal Inference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32 b

Indigo D 32 A

1.0 hr.

11:00 am –12:30 pm

aCr Plenary session i: discovery 2013 . . . . . . . . . . . . . . . . . . .Abstracts (#761-765)

Hall b1 1.5 hrs.


10




12:30 –1:15 pm

innovation theaterSee�page�XX�for�the�Innovation�Theater�Listing . . . . . . . . . . . . . . . .


12:30 –2:00 pm

aCr sessions opportunities for Social Media in Medical education . . . . .

Why every U.S. rheumatologist Should Join the National rheumatology registry (rISe) PM PS . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire A

Sapphire I

1.5 hrs.

1.5 hrs.

12:30 –2:15 pm

arHP networking eventArHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sapphire L

12:45 –2:15 pm

aCr sessionAcr Knowledge bowl– Preliminary round . . . . . . . . . . . . . . . . ballroom 20 A

12:45 –2:15 pm

aCr meet the Professor sessions Adult Inflammatory Myopathy (011) . . . . . . . . . . . . . . . . . . . . . . . . . .

behçet's Disease (012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

cutaneous Vasculitis (013) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Fibromylagia 2013: Update on Management (014) PM PS . . . . . .

Hereditary Angioedema Update (015) . . . . . . . . . . . . . . . . . . . . . . . . .

Inflammatory eye Disease/Uveitis (016) . . . . . . . . . . . . . . . . . . . . . . .

reactive Arthritis: An Update (017) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Scleroderma Mimics (018) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Systemic Lupus erythematosus: Lupus Nephritis (019) . . . . . . .

Understanding of Approach to the care of Patients with Vasculitis (020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A14 b15 A15 b16 A16 b17 A 17 b

1.5 hrs.

1:00 –2:00 pm

aCr sessions Alopecia 101 for the rheumatologist . . . . . . . . . . . . . . . . . . . . . Mechanisms of Pain in osteoarthritis PM PS . . . . . . . . . . . . . . . .

telomeres, telomerase and Age-related Disease . . . . . . . . .

6 A30 e

Indigo c

1.0 hr.

1:15 –3:15 pm

aCr workshops beyond Musculoskeletal Ultrasound for rheumatologists (209) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

clinical Anatomy and Physical exam: essential tools in Lower extremity regional Pain Syndromes (210) PM PS . . . . . . . . . . . . . . . . osteoporosis: Interpreting Dual energy X-ray Absorptiometry and clinical risk Factors: the New Fracture risk Assessment Algorithm (211) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4 2 1 A

2.0 hrs.

2:30 –3:15 pm




cANceLLeD

11

SUNDAY, OCTOBER 27 Meeting At-A-Glance


2:30 –4:00 pm

aCr sessions Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy . . . . . . . .

osteoarthritis Pathophysiology, Diagnosis and Management: What can I tell my osteoarthritis Patient to Do other than Weight Loss and Quadriceps Strengthening? . . . . . . . . . . . . . .

Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

the Great Debate: biologics or triple therapy for the treatment of rheumatoid Arthritis? PM PS . . . . . . . . . . . . . . . . . Vascular Disease in Scleroderma: A Multi-organ challenge . .

Indigo e

ballroom 20 A 6 D Hall b16 A

1.5 hrs.

2:30 –4:00 pm

aCr Concurrent abstract sessions (#766–771) biology and Pathology of bone and Joint I: cartilage biology and osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#772–777) cytokines, Mediators, cell-cell Adhesion, cell trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and cell trafficking . . . . . . . .

(#778-783) epidemiology and Health Services research I: comorbidities in rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . .

(#784-789) Miscellaneous rheumatic Diseases . . . . . . . . . . . . . . .

(#790-795) Pediatric rheumatology: clinical and therapeutic Disease: Juvenile Idiopathic Arthritis . . . . . . . . . . . .

(#796-801) rheumatoid Arthritis - clinical Aspects I: treatment Strategies in rheumatoid Arthritis . . . . . . . . . . . . . . . . .

(#802-807) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: Safety Issues . . . . . . . .

(#808-813) rheumatoid Arthritis- Autoantibodies and citrullinated Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#814-819) Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment: therapeutics and outcomes in Psoriatic Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#820-825) Systemic Sclerosis, Fibrosing Syndromes and raynaud’s – Pathogenesis, Animal Models and Genetics I: therapeutic Interventions in Preclinical Animal Models of Sclerodermaoderma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

202 A

28 b

306 A29 D 28 D 6 c 30 e

204 A 33 A

Indigo c

1.5 hrs.

2:30 –4:00 pm

aCr/arHP Combined abstract session (#826-831) Acr/ArHP combined rehabilitation Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

31 c

1.5 hrs.

2:30 –4:00 pm

arHP sessions best Practices for Diagnostic Imaging in evaluating rheumatologic conditions PM PS PM PS . . . . . . . . . . . . . . . . . . . . . . . Influence of cardiac comorbidities on exercise in Individuals With rheumatic Diseases PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Juvenile Systemic Lupus erythematosus PM PS . . . . . . . . . . . . .

Indigo D

Sapphire A

Sapphire I

1.5 hrs.






2:30 –4:00 pm

arHP Concurrent abstract sessions (#832-837) ArHP Noteworthy Abstracts . . . . . . . . . . . . . . . . . . . . . . 32 b

1.5 hrs.

4:00 –6:00 pm

aCr workshopsJoint Injection techniques (212) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Musculoskeletal exam Skills I: General Musculoskeletal examination for Arthritis (213) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Musculoskeletal Ultrasonography: basic (214) . . . . . . . . . . . . . . . .

Synovial Fluid Analysis and crystal Identification (215) . . . . . . .

2 341 b

2.0 hrs.

4:30 –5:30 pm

arHP sessionrheumatic Disease Update: A review of Inflammatory Myositis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indigo D

1.5 hrs.

4:30 –6:00 pm

aCr sessions oA-oMIcS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pediatric Inflammatory brain Diseases . . . . . . . . . . . . . . . . . . . . Quality Measures in rheumatology: Developing and Implementing Meaningful Measures as Health care reform Advances PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . regenerative and Stem cell Medicine . . . . . . . . . . . . . . . . . . . . . Sex and Autoimmunity: Hormones and beyond . . . . . . . . . . thieves’ Market: Show Me Your best cases . . . . . . . . . . . . . . .

6 c30 e 6 Aballroom 20 A

Indigo eHall b1

1.5 hrs.

4:30 –6:00 pm

aCr Concurrent abstract sessions (#838-843) Fibromyalgia, Soft tissue Disorders and Pain: Diagnosis and Disease epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . .

(#844-849) Health Services research, Quality Measures and Quality of care - Pediatrics, Immunization and -choosing Wisely . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#850-855) Imaging of rheumatic Diseases: Imaging in Vascular and extra-articular . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#856-861) Metabolic and crystal Arthropathies I . . . . . . . . . . . .

(#862-867) osteoporosis and Metabolic bone Disease: clinical Aspects and Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#868-873) rheumatoid Arthritis - clinical Aspects II: Identifying rheumatoid Arthritis in At-risk Populations . . . . . .

(#874-879) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: efficacy of Approved biologics II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#880-885) Systemic Lupus erythematosus - clinical Aspects and treatment: Lupus Nephritis and Genetics . . . . . . .

(#886-890) Systemic Lupus erythematosus - Human etiology and Pathogenesis I Includes�2012�Lee�C.�Howley,�Sr.�Prize�for�Arthtritis� Research Introductory Talk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#891-896) Vasculitis I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire I

28 D 31 c

Sapphire A

202 A

29 D 6 D 33 A

Indigo c28 b

1.5 hrs.



SUNDAY & MONDAY, OCTOBER 27 – 28 Meeting At-A-Glance


4:30 –6:00 pm

aCr meet the Professor sessions Ankylosing Spondylitis: 2013 Update (021) PM PS . . . . . . . . . . . . . . .


Juvenile Dermatomyositis (023) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . osteoarthritis: Update 2013 (024) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pain: evaluation and treatment of back Pain (025) PM PS . . . . . .

rheumatoid Arthritis: biological Agents (026) PM PS . . . . . . . . . . . .


Systemic Lupus erythematosus: Novel treatments (028) . . . . .

Systemic Sclerosis: Disease Staging and Subsetting in clinical Practice (029) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vasculitis: Update (030) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A14 b15 A15 b16 A16 b 17 A17 b

1.5 hrs.

4:30 –6:00 pm

arHP sessions "Fine tuning" Your Skills in Utilizing Disease Activity Measurement tools for rheumatic Arthritis . . . . . . . . . . . . . . Postural changes: How to Improve Joint Protection, Strength and Gait efficiency PM PS PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32 A

204 A

1.5 hrs.

4:30 –6:00 pm

arHP Concurrent abstract sessions (#897-902) epidemiology and Public Health . . . . . . . . . . . . . . . . . .

(#903-908) Psychology/Social Sciences . . . . . . . . . . . . . . . . . . . . . . . . 306 A

32 b

1.5 hrs.

6:30 –9:30 pm

industry-supported symposia See�program�book�page�353�for�the�list�of�symposia.

MONdAy, OCTObeR 28, 2013


7:00 am – 6:00 pm


Sails Pavilion

7:30 – 8:30 am

aCr sessions clinicopathologic conference: A Patient with rheumatoid Arthritis and Systemic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

IL-6, the Pleiotrophic cytokine: New clinical roles and therapeutic opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Medical Marijuana and the rheumatologist PM PS PM PS . . . . Mitigating Health Disparities in rheumatologic Disease PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

tyro3/Axl/Mer (tAM) receptors and Innate Immune regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall b1 6 Aballroom 20 A 32 b 6 D

1.0 hr.

14

Meeting At-A-Glance MONDAY, OCTOBER 28



7:30 –8:30 am

arHP sessions An overview of Qualitative research . . . . . . . . . . . . . . . . . . . . . . Immunology boot camp Session 2: the basics of Autoimmunity and Immunodeficiency – When “Good cells Go bad” . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Piloting Your research to Success: the Why, What and How of Pilot Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire A

Indigo D

204 A

1.0 hr.

7:30 –9:00 am

aCr sessionImproving Quality, outcomes and Spending in Health care: Good Data and Measures Are Just the beginning . . . .

202 A

1.5 hrs.

7:45 –9:15 am

aCr meet the Professors Antiphospholipid Syndrome (031) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

calcium crystal Arthritis (032) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

controversies in Sjögren's Syndrome (033) . . . . . . . . . . . . . . . . . . . .

Dermatological Manifestations of rheumatic Diseases (034) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Infections with biologics (035) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatrics: Periodic Fevers in children (036) . . . . . . . . . . . . . . . . . . Pregnancy and rheumatic Diseases (037) . . . . . . . . . . . . . . . . . . . . .

Systemic Lupus erythematosus: central Nervous System (038) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vasculitis Mimics (039) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vitamin D and bone Health (040) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A 14 b15 A15 b16 A 16 b17 A17 b

1.5 hrs.

7:45 –9:45 am

aCr workshops clinical Anatomy and Physical exam: essential tools in Upper extremity regional Pain Syndromes (216) PM PS . . . . . . . . . . . . . . . . Musculoskeletal Ultrasonography: basic (217) . . . . . . . . . . . . . . . .

X-ray challenges in rheumatic Diseases (218). . . . . . . . . . . . . . . . .

241b

2.0 hrs.

8:30 –10:00 am

aCr sessions Atypical Myopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Good reviewers Make Good Authors: A Guide to conducting excellent Manuscript reviews . . . . . . . . . . . . . Kawasaki Disease: Putting out the Fire . . . . . . . . . . . . . . . . Rheumatology�Research�Foundation Special Session: clinician Scholar educators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom 20 A

306 A

6 c 28 b

1.5 hrs.


15

MONDAY, OCTOBER 28 Meeting At-A-Glance



8:30 am –4:00 pm

aCr/arHP Poster session B, thieves’ market Posters and Poster tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Abstracts (#909-1689)

Poster Hall Morning Snack break (8:30 – 10:00 am)


guided Poster tours9:00 – 9:45 am313 – epidemiology and Health Services research Poster tour 314 – Imaging of rheumatic Diseases Poster tour 315 – Pediatric rheumatology: clinical Aspects Poster tour 316 – rheumatoid Arthritis treatment - Small Molecules,

biologics and Gene therapy Poster tour 317 – rheumatoid Arthritis: clinical Aspects Poster tour 318 – Spondylarthropathies and Psoriatic Arthritis: clinical

Aspects and treatment Poster tour

10:15 – 11:00 am319 – Pediatric rheumatology: clinical Aspects Poster tour 320 – rheumatoid Arthritis treatment - Small Molecules,

biologics and Gene therapy Poster tour 321 – rheumatoid Arthritis: clinical Aspects Poster tours 322 – Spondylarthropathies and Psoriatic Arthritis: clinical

Aspects and treatment Poster tour 323 – Systemic Lupus erythematosus: Human etiology and

Pathogenesis Poster tour 324 – Vasculitis Poster tour


2.0 hrs.

9:00 –10:00 am

aCr sessions How to Maintain Your Medical License and certification After 2013: changes Will Impact All Physicians. Are You Prepared? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poor Sleep: consequences and cures . . . . . . . . . . . . . . . . . . . . .

30 eHall b1

1.0 hr.

9:00 –10:00 am

arHP sessions Distinguished Lecturer: Integrating concepts of behavioral change and technology to Promote Health in Persons With Arthritis PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indigo D

1.0 hr.

10:00 am –5:00 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall Morning Snack break (10:00 – 11:00 am)exhibit Hall Afternoon Snack break (2:00 –3:00 pm)

exhibit Hall F-G

0 hrs.


16




10:30 –11:15 am

innovation theaterSee�page�XX�for�the�Innovation�Theater�Listing . . . . . . . . . . . . . . . .


10:30 am –12:30 pm

aCr/arHP workshopsDermatopathology of rheumatic Diseases (219) . . . . . . . . . . . . . .

Joint Injections (Knee, Ankle, Shoulder and Wrist) (220) . . . . . .

Musculoskeletal exam Skills II: regional Musculoskeletal examination of the Neck and Low back (221) . . . . . . . . . . . . . . . . .

renal Histopathology in Systemic Lupus erythematosus and Vasculitis (222) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1 A2 3 1 b

2.0 hrs.

11:00 am –Noon

aCr sessions Acr Knowledge bowl–Final round . . . . . . . . . . . . . . . . . . . . . . . .

Personalized Medicine: transforming 300 billion Points of Data into Diagnostics, therapeutics, and New Insights into Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rheumatology�Research�Foundation Paul Klemperer, MD, Memorial Lectureship: rheumatoid Arthritis and Autoimmunity: Good Genes, elegant Mechanisms, bad results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom 20 A 30 e Hall b1

1.0 hr.

11:00 am –Noon

arHP sessions Navigating the System: the Key to obtaining Medications for Your Patients PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . obesity and rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . rheumatic Manifestations of endocrine Disorders . . . . . . .

Sapphire I

29 D Indigo D

1.0 hr.

11:00 am –12:30 pm

aCr Plenary session ii: discovery 2013 Abstracts (#1690-1695) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 A

1.5 hrs.

Noon –2:00 pm

arHP networking event ArHP Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire L

12:30 –1:15 pm



12:30 –2:00 pm

aCr sessions Acr Special Session: career opportunities in rheumatology: Making a choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Inter-professional collaborative Practice and education: A review of the Field and report of a New center of excellence in Musculoskeletal care PM PS . . . . . . . . . . . . . . . . . . .

Indigo c

Sapphire I

1.5 hrs.


17




12:45 –2:15 pm

aCr meet the Professor sessions challenging cases in osteoporosis Management (041) . . . . . . .

Immunodeficiency Syndromes (042) . . . . . . . . . . . . . . . . . . . . . . . . . .

Macrophage Activation Syndrome (043) . . . . . . . . . . . . . . . . . . . . . .

Myopathy: Issues in Diagnosis and treatment (044) . . . . . . . . . .

Pulmonary Manifestations of rheumatic Disease (045) . . . . . .

raynaud's and Digital Ischemia (046) . . . . . . . . . . . . . . . . . . . . . . . . . .

rheumatoid Arthritis: biological Agents (047). . . . . . . . . . . . . . . . .

rheumatoid Arthritis: Safety of Novel therapies (048) PM PS . .

Systemic Lupus erythematosus: Difficult to treat Systemic Lupus erythematosus (049) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

What is Not central Nervous Angiitis: Making the right Diagnosis (050) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A14 b15 A15 b16 A16 b 17 A 17 b

1.5 hrs.

1:00 –2:00 pm

aCr sessions behçet’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Winning at clue: the clinical rheumatologist's Guide to Figuring out Who Killed Who, With What and Where in the rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 A ballroom 20 A

1.0 hr..

1:15 –3:15 pm

aCr workshops Magnetic resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A clinician's Guide (223) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Peripheral Magnetic resonance Imaging in rheumatology Practice (224) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Synovial Fluid Analysis and crystal Identification (225) . . . . . . .

4 1 A1 b

2.0 hrs.

2:30 –3:15 pm



2:30 –4:00 pm

aCr sessions Autoimmunity caused by Immune Deficiency: When Not enough Is too Much . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . crystal Diseases: How Does Joint Damage occur and Why do Attacks resolve Spontaneously? . . . . . . . . . . . . . . . . . . . . . . . curbside consults – Ask the experts . . . . . . . . . . . . . . . . . . . . . .

Functional Genomics: Approaches to Identifying causal Variants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Janus Kinase (JAK) Inhibitors in rheumatoid Arthritis . . . .

6 c 6 AHall b1 6 Dballroom 20 A

1.5 hrs.





2:30 –4:00 pm

aCr Concurrent abstract sessions *(#1696-1700, 1062) epidemiology and Health Services research II: epidemiology in Systemic Lupus erythematosus and rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1702-1707) Genetics and Genomics of rheumatic Disease I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

*(#1720-1724, 1190) Health Services research, Quality Measures and Quality of care – rheumatoid Arthritis . . . . . . . .

(#1714-1719) Imaging in Pediatric Arthritis, Spondyloarthritis, and osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . .

*(#1720-1724, 1190) Metabolic and crystal Arthropathies II .(#1726-1731) rheumatoid Arthritis - Animal Models I . . . . . . . .

(#1732-1737) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: efficacy and Safety of Novel entities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1738-1743)Systemic Lupus erythematosus - clinical Aspects and treatment: biologic therapy . . . . . . . . . . . . . . . . . . . . .

(#1744-1749) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s - clinical Aspects and therapeutics I . . . . . . . . . .

(#1750-1755) Vasculitis II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

* break in presentation number sequence is due to the addition of a substitute abstract.

31 c

204 A 28 D

306 A Indigo e

32 b 29 D 33 A

Sapphire A

30 e

1.5 hrs.

2:30 –4:00 pm

aCr/arHP Combined abstract session (#1756-1761) Acr/ArHP combined epidemiology Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indigo c

1.5 hrs.

2:30 –4:00 pm

arHP sessions Aerobic, Strength and biomechanical considerations for treatment Progression in osteoarthritis: What is the evidence? PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Designing a Qualitative Study and An example of the Use of Qualitative Study Design in Patients With rheumatologic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . rheumatic Disease Update Debate: calcium and Vitamin D, What Does the research Support? PM PS . . . . . . . . . . . . . . . . . . .

rheumatic Diseases in Women of childbearing Years: Fertility, Pregnancy and Lactation . . . . . . . . . . . . . . . . . . . . . . . . .

32 A

Sapphire I

Indigo D

28 b

1.5 hrs.





4:00 –6:00 pm

aCr/arHP workshops Getting electronic Health records right (226) PM PS . . . . . . . Musculoskeletal exam Skills III: regional Musculoskeletal examination of the Shoulder and Knee (227) . . . . . . . . . . . . . . . . .

Musculoskeletal Ultrasound (228) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

the rheumatologic Musculoskeletal Screening exam, with emphasis on objective Disease-specific Measurements (229) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1 A 34 2

2.0 hrs.

4:30 –6:00 pm

aCr sessions bone is Hard or is it? Mechanisms regulating bone Qualities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

challenges in Systemic Lupus erythematosus Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gout and Pseudogout: What’s New in treatments and Diagnostic Modalities? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Inflammasomes in Health and Disease . . . . . . . . . . . . . . . . . . . . Updated Acr recommendations for the treatment of Juvenile Idiopathic Arthritis PM PS . . . . . . . . . . . . . . . . . . . . . . . .

6 c Hall b1 ballroom 20 A6 D

Indigo e

1.5 hrs.

4:30 –6:00 pm

aCr Concurrent abstract sessions (#1762-1767) cytokines, Mediators, cell-cell Adhesion, cell trafficking and Angiogenesis II: Mechanisms that ccontribute to Autoimmune Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1768-1773) epidemiology and Health Services research II: Healthcare costs and Mortality in rheumatic Disease . . . . . . . .

(#1774-1779) Muscle biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1780-1785) Pediatric rheumatology - clinical and therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1786-1791) rheumatoid Arthritis - clinical Aspects III: Predictors of Disease course in rheumatoid Arthritis . . . . . . . .

(#1792-1797) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: Safety and efficacy of Small Molecule Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1798-1803) Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment: therapeutics and outcomes in Spondyloarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1804-1809) Systemic Lupus erythematosus - clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#1810-1815) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s - clinical Aspects and therapeutics II . . . . . . . . . . . . . .

Sapphire A

31 c

Indigo D 32 b

Indigo c 30 e 29 D 33 A 28 b

1.5 hrs.





4:30 –6:00 pm

aCr meet the Professor sessions Ankylosing Spondylitis: Disease Modification (051) . . . . . . . . . . .

basic Immunology for clinical rheumatologists (052) . . . . . . . .

Pain: evaluation and treatment of back Pain (053) PM PS . . . . . . Pediatric rheumatology for Adult rheumatologists (054) . . . . Polymyalgia rheumatica (055) PM PS PM PS . . . . . . . . . . . . . . . . . . . . . . .

Psoriatic Arthritis (056) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pulmonary Hypertension in the rheumatic Diseases (057) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


temporal Arteritis (059) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vaccinations for Patients on biologic therapies (060) PM PS . . . .

121314 A14 b15 A15 b 16 A16 b17 A17 b

1.5 hrs.

4:30 –6:00 pm

arHP sessions body Image with rheumatic conditions . . . . . . . . . . . . . . . . . . rheumatoid Arthritis Management: Views from Around the World PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Work, Health and Well-being: Arthritis and employment Across the Life Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire I

28 D

306 A

1.5 hr..

4:30 –6:00 pm

arHP Concurrent abstract sessions (#1816-1821) rehabilitation Sciences . . . . . . . . . . . . . . . . . . . . . . . . . 32 A

1.5 hrs.

6:30 –7:45 pm

aCr study groups Acr Musculoskeletal Ultrasound Study Group . . . . . . . . . . . . . . . .

Acr-eULAr exchange Study Group – Joint Imaging and Beyond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Autoantibodies in Diagnosis and Follow-up of rheumatic Diseases Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

behҫet's Syndrome Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

biosimilars in rheumatology Study Group . . . . . . . . . . . . . . . . . . . .

capillaroscopy in rheumatic Diseases Study Group . . . . . . . . . . . crystal Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Decision Aids in rheumatology Study Group . . . . . . . . . . . . . . . . . .

Global Musculoskeletal Health Initiative Study Group . . . . . . . .

High-resolution Peripheral Quantitative computed tomography (Hr-pQct) – early Damage Detection in Inflammatory and Degenerative Arthritis . . . . . . . . . . . . . . . . . . . . .

JAW (Juvenile Arthritis Workgroup) . . . . . . . . . . . . . . . . . . . . . . . . . . .

Latin American Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Neuro endocrine Immunology Study Group . . . . . . . . . . . . . . . . . . .

Pediatric rheumatology Imaging Study Group . . . . . . . . . . . . . . . .

Polymyalgia rheumatica Study Group . . . . . . . . . . . . . . . . . . . . . . . . .

Primary Sjögren's Syndrome Study Group . . . . . . . . . . . . . . . . . . . . .

Veterans Affairs rheumatology Study Group . . . . . . . . . . . . . . . . . .

33 A-b-c 15 A 32 A30 e1231 c29 D28 D13 14 A16 b32 b14 b15 b16 A17 A28 b



TUESDAY, OCTOBER 29 Meeting At-A-Glance


TueSdAy, OCTObeR 29, 2013


7:00 am – 6:00 pm


Sails Pavilion

7:30 –8:30 am

aCr sessions care of chronic Non-Healing Wounds PM PS PM PS . . . . . . . . . . . Non-coding DNA: Signals, Switches, and complex regulation of Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatric Autoimmune and Inflammatory Skin Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall b1 30 e 6 c

1.0 hrs.

7:30 –8:30 am

arHP sessions rheumatic Disease and Pain Management in Special Needs Populations PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . rheumatology Update: Inflammatory bowel Disease . . . . the results Section in Medical research Literature: the Appropriate and Inappropriate Use of Statistics PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

204 A Indigo D

32 b

1.0 hr.

7:30 –9:00 am

aCr sessions Rheumatology�Research�Foundation Special Session: Disease targeted research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . risk Management–A case Study PM PS . . . . . . . . . . . . . . . . . . . . .

Indigo c Sapphire I

1.5 hrs.

7:45 –9:15 am

aCr meet the Professors Ankylosing Spondylitis: 2013 Update (061) PM PS . . . . . . . . . . . . . . .

Antiphospholipid Syndrome (062) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Myopathy: Issues in Diagnosis and treatment (064) . . . . . . . . . .

osteoporosis: Novel treatments (065) . . . . . . . . . . . . . . . . . . . . . . . .

Pregnancy and rheumatic Diseases (066) . . . . . . . . . . . . . . . . . . . . .

rheumatoid Arthritis: Safety of Novel therapies (067) PM PS . . . .

rheumatology Practice 101: Starting out in Practice for the Graduating Fellow (068) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Systemic Sclerosis: Disease Staging and Subsetting in clinical Practice (069) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

temporal Arteritis (070) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A14 b15 A15 b16 A 16 b 17 A17 b

1.5 hrs.

7:45 –9:45 am

aCr/arHP workshops Advanced Musculoskeletal Ultrasound (230) . . . . . . . . . . . . . . . . . .

Histopathology of Vasculitis (231) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Joint Injections (Knee, Ankle, Shoulder and Wrist) (232) . . . . . .

Knee braces and Foot orthosis for Knee osteoarthritis (233) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

41 A2 3

2.0 hrs.

22

Meeting At-A-Glance TUESDAY, OCTOBER 29



8:00 –9:30 am

aCr session contract Negotiations for Physicians . . . . . . . . . . . . . . . . . . . . . . 28 D

1.5 hrs.

8:30 –10:00 am

aCr sessions chart etiquette: creating Meaningful Notes PM PS . . . . . . . . . choosing and Monitoring rheumatoid Arthritis therapy in 2013 PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

31 c ballroom 20 A

1.5 hrs.

8:30 am –4:00 pm

aCr/arHP Poster session C, thieves’ market Posters, late-breaking Posters and Poster tours . . . . . . . . . . . . . . . . . . . . . .Abstracts (#1822-2643)


guided Poster tours9:00 – 9:45 am325 – Antiphospolipid Syndrome Poster tour326 – Miscellaneous rheumatic and Inflammatory Diseases

Poster Tour 327 – rheumatoid Arthritis: clinical Aspects Poster tour 328 – rheumatoid Arthritis: Human etiology and

Pathogenesis Poster tour 329 – Rheumatology�Research�Foundation Poster tour:

Designing A clinical Study for rheumatic Disease 330 – Spondylarthropathies and Psoriatic Arthritis: clinical

Aspects and treatment Poster tour

10:15 – 11:00 am331 – Metabolic and crystal Arthropathies Poster tour 332 – Muscle biology, Myositis and Myopathies Poster tour 333 – Pediatric rheumatology: clinical Aspects Poster tour 334 – rheumatoid Arthritis - Small Molecules, biologics and

Gene therapy Poster tour 335 – Systemic Sclerosis, Fibrosing Syndromes, and

raynaud’s - clinical Aspects and therapeutics Poster Tour

336 – Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment Poster tour


2.0 hrs.

9:00 –10:00 am

aCr sessions ready or Not…It’s coming: Implementation of IcD-10 PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . the role of b cells in rheumatic Disease . . . . . . . . . . . . . . . . . . the role of th17 cells in Health and Disease . . . . . . . . . . . . .

202 A

6 A6 D

1.0 hr.


23



9:00 –10:00 am

arHP sessions An Integrative Approach to Pediatric Wellness PM PS . . . . . . Anxiety Disorders in rheumatic Disease . . . . . . . . . . . . . . . . . . Immunology boot camp Session 3: biologic Logic, An Update

PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Knowledge Is Power, but Sample Size Matters More: the role of Sample Size in the Power and Precision of Study results PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32 b 306 A

Indigo D

204 A

1.0 hr.

10:00 am –2:30 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall Morning Snack break (10:00 – 11:00 am)exhibit Hall F-G

10:30 –11:15 am



10:30 am –12:30 pm

aCr/arHP workshops Musculoskeletal Ultrasound (234) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

tai chi and Alternative therapies in rheumatic (235) PM PS . . . .

the rheumatologic Musculoskeletal Screening exam, with emphasis on objective Disease-specific Measurements (236) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

43 1 b

2.0 hrs.

11:00 am –Noon

aCr session Mechanics, Matrix Disruption, and the Development of osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

30 e

1.5 hrs.

11:00 am –Noon

arHP sessions Nonalcoholic Fatty Liver Disease . . . . . . . . . . . . . . . . . . . . . . . . . . oral Health in rheumatologic Disease . . . . . . . . . . . . . . . . . . . . Persistent Pain: Mechanisms of chronic Pain and Innovative treatment options PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire A

Sapphire I

28 b

1.0 hr.

11:00 am –12:30 pm

aCr sessions Assessment tool Selection in Health Professions education PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Audits – Are You At risk? PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Protein citrullination and biological response Modification: rheumatoid Arthritis and beyond . . . . . . . . . . Selected topics related to Spondylarthropathies PM PS . . . .

306 A

32 A ballroom 20 AHall b1

1.5 hrs.

11:00 am –12:30 pm

aCr Plenary session iii: discovery 2013Abstracts (#2644-2649) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 A

1.5 hrs.



24



12:30 –1:15 pm



12:45 –2:15 pm

aCr meet the Professor sessions Adult Inflammatory Myopathy (071) . . . . . . . . . . . . . . . . . . . . . . . . . .

basic Immunology for clinical rheumatologists (072) . . . . . . . .

behçet's Disease (073) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Infections with biologics (074) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatrics: Difficult to treat Juvenile Idiopathic Arthritis (075) . . Psoriatic Arthritis (076) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

rheumatoid Arthritis: biological Agents (077). . . . . . . . . . . . . . . . .


Systemic Lupus erythematosus: Lupus Nephritis (079) . . . . . . .

Vasculitis: Update (080) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121314 A14 b15 A15 b16 A16 b17 A17 b

1.5 hrs.

1:00 –2:00 pm

aCr sessions Animal Models in rheumatic Disease—How Useful Are they? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hench Lecture: evolutionary Medicine and chronic Inflammatory State – Known and New concepts in Pathophysiology PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Inflammatory eye Disease: An Update for rheumatologists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 c ballroom 20 A Hall b1

1.0 hr.

1:00 –2:00 pm

study groups A Multi-Disciplinary Approach to Post Fracture Management Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Antiphospholipid Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

expert Journal club Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gout classification criteria Study Group . . . . . . . . . . . . . . . . . . . . . .

Hypermobility Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Interstitial Lung Diseases in connective tissue Disease Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Macrophage Activation Syndrome Study Group . . . . . . . . . . . . . .

Myositis Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-Vasculitic Vasculopathy Study Group . . . . . . . . . . . . . . . . . . . . .

osteoarthritis Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Spondylarthritis Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

takayasu's Arteritis Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

31 c32 A

306 A32 b

Sapphire A

28 D

Indigo c

Indigo D

Sapphire I

29 D 202 A

28 b



cANceLLeD




1:15 –3:15 pm

aCr workshops Joint Injection techniques (237) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

osteoporosis: Interpreting Dual energy X-ray Absorptiometry and clinical risk Factors: the New Fracture risk Assessment Algorithm (238) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

renal Histopathology in Systemic Lupus erythematosus and Vasculitis (239) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2 1 A 1 b

1.5 hrs.

1:30 –2:00 pm

aCr session Acr business Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 A

2:30 –4:00 pm

aCr sessions Adipose tissue and Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . Novel Insight into the Pathogenesis of Systemic Vasculitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . osteoporosis treatment Strategies for today and tomorrow . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vaccinology and DMArD Use in Immunocompromised and High-risk Populations PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 D

Indigo e Hall b1 ballroom 20 A

1.5 hrs.

2:30 –4:00 pm

aCr Concurrent abstract sessions Late-breaking Abstracts Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2650-2655) Antiphospholipid Syndrome . . . . . . . . . . . . . . . . . . . .

(#2656-2661) epidemiology and Health Services research VI: risk Factors in rheumatic Disease Susceptibility . . . . . . . . . .

(#2662-2667) Health Services research, Quality Measures and Quality of care - Innovations in Health care Delivery . . . .

(#2668-2673) osteoarthritis I: therapeutics in osteoarthritis . . .

(#2674-2679) Pediatric rheumatology - clinical and therapeutic Aspects III: Systemic Lupus erythematosus and other Disease outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2680-2685) rheumatoid Arthritis - clinical Aspects IV: comorbidities in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . .

(#2686-2691) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: Novel treatment Strategies in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2692-2697) Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2698-2703) Systemic Lupus erythematosus - Human etiology and Pathogenesis II . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2704-2709) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s II: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis . . . . . . . . . . . . . . . . . . . . . . . .

(#2710, 2714, 710) t-cell biology and targets in Autoimmune Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

* break in presentation number sequence is due to the addition of a substitute abstract.

6 A Indigo D

28 b 28 D306 A

Sapphire A

33 A 6 c 31 c 30 e 32 A 29 D

1.5 hrs.





2:30 –4:00 pm

arHP sessionsDefining the roles of the rheumatology Nurse Internationally . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot care Interventions PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . You can Improve Hand Function in Scleroderma PM PS PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sapphire I

202 A32 b

1.5 hrs.

2:30 –4:00 pm

arHP Concurrent abstract session (#2716-2721) clinical Practice/Patient care . . . . . . . . . . . . . . . . . . . 204 A

1.5 hrs.

4:00 –6:00 pm

aCr workshops Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data 3 and beyond toward a Standard, Scientific, Quantitative Patient History (240) PM PS . . . . . . . . . . . . . . . . . . . . . . . .

Proficiency in teaching: engaging Learners (241) . . . . . . . . . . . . .

Systemic Sclerosis: How to Perform Skin Scores (242) . . . . . . . .

1 A43

2.0 hrs.

4:30 –6:00 pm

aCr sessions cell Death and toll-like receptor (tLr) recognition of Nucleic Acid Ligands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . critical care rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ILAr – Pediatric rheumatology in Developing Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Large Vessel Vasculitis: What Should the clinician Know . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Update on Safety Issues in the treatment of rheumatic Diseases – From the FDA and beyond PM PS . . . . . . . . . . . . . . . .

Indigo e

ballroom 20 A 32 A Hall b1 6 A

1.5 hrs.





4:30 –6:00 pm

aCr Concurrent abstract sessions (#2722-2727) 2013 Rheumatology�Research�Foundation edmond L. Dubois, MD Memorial Lectureship . . . . . . . . . . . . . . . .

(#2728-2733) biology and Pathology of bone and Joint II: osteoclast biology and Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2734-2739) Genetics and Genomics of rheumatic Disease II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2740-2745) Innate Immunity and rheumatic Disease . . . . . .

(#2746-2751) Miscellaneous rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes . . . . . . . . . . . . . . . . . . . . .

(#2752-2757) osteoarthritis II: risk Factors and Natural History of osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2758-2763) rheumatoid Arthritis - clinical Aspects V: observational Studies in rheumatoid Arthritis . . . . . . . . . . . . . . . .

(#2764-2769) rheumatoid Arthritis treatment - Small Molecules, biologics and Gene therapy: efficacy of Approved biologics I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2770-2775) Sjögren’s Syndrome: basic Science . . . . . . . . . . . . .

(#2776-2781) Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment: clinical Features of Spondyloarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2782-2787) Vasculitis III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 c

Indigo D

Sapphire A

31 c 29 D

306 A 6 D 30 e28 D 33 A28 b

1.5 hrs.

4:30 pm –6:00 pm

aCr meet the Professor sessions controversies in Sjögren's Syndrome (081) . . . . . . . . . . . . . . . . . . . .

osteoarthritis: Update 2013 (082) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pulmonary Manifestations of rheumatic Disease (083) . . . . . .

raynaud's and Digital Ischemia (084) . . . . . . . . . . . . . . . . . . . . . . . . . .

reactive Arthritis: An Update (085) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Still's Disease and AutoInflammatory Syndromes (086) . . . . . . .

Systemic Lupus erythematosus: central Nervous System (087) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Systemic Lupus erythematosus: Difficult to treat Systemic Lupus erythematosus (088) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Understanding of Approach to the care of Patients with Vasculitis (089) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vaccinations for Patients on biologic therapies (090) PM PS . . . .

121314 A14 b15 A15 b 16 A 16 b 17 A17 b

1.5 hrs.

4:30 –6:00 pm

aCr/arHP Combined abstract session (#2788-2793) Acr/ArHP combined Pediatrics Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indigo c

1.5 hrs.



Meeting At-A-Glance TUESDAY & WEDNESDAY, OCTOBER 29 – 30


4:30 –6:00 pm

arHP sessionsenhancing clinical Practice with Patient engagement and Self-management Support Strategies PM PS . . . . . . . . . . . . . . . . Pharmacist/Physician Partnership in rheumatic Disease Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

the Age of Information technology: registries, Administrative Databases, and the role of the Internet in rheumatic Disease research PM PS . . . . . . . . . . . . . . . . . . . . . . . . .

204 A

202 A

Sapphire I

1.5 hrs.

6:30 –9:30 pm

industry-supported symposia See�program�book�page�31�for�the�list�of�symposia.

wedNeSdAy, OCTObeR 30, 2013


7:00 am – 1:00 pm


Sails Pavilion

7:00 AM – 8:30 PM

aCr Concurrent abstract session(#2914-2919) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s - clinical Aspects and therapeutics III . . . . . . . . . . . . . .

30 e

1.5 hrs

7:30 AM – 8:30 PM

aCr sessions Glycoregulation of Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . Microparticles: real effectors or Just Mini-Me . . . . . . . . . . . . rheumatology roundup: Highlights from the 2013 Annual Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6 c6 A Hall b1

1.0 hr.

7:30 –8:30 am

arHP sessions rheumatic Disease Update: rheumatoid Arthritis . . . . . . . . the risks, Screening and Management of Human Papillomavirus in Patients with rheumatologic Disease . . .

Indigo D

28 b

1.0 hr.

9:00 –10:00 am

aCr session emerging and Unexpected regulatory roles for complement in the rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom 20 A

1.0 hr.

9:00 –10:30 am

aCr sessions current Management of Sjögren’s Syndrome . . . . . . . . . . . . . Molecular and cellular Profiling of the Immune response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Patient-reported outcome Measures for rheumatologists PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Policy changes that Will Affect Your Practice in 2014: Meaningful Use, Value-based Purchasing, Physician Quality reporting System (PQrS) and IcD-10 PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall b1 6 c 6 A

Sapphire A

1.5 hrs.


WEDNESDAY, OCTOBER 30 Meeting At-A-Glance


9:00 –10:30 am

aCr Concurrent abstract sessions (#2794-2799) b cells in Systemic Lupus erythematosus . . . . . . .

(#2800-2805) Imaging in rheumatoid Arthritis . . . . . . . . . . . . . . .

(#2806-2811) Infection related rheumatic Diseases. . . . . . . . . .

(#2812-2817) Medical education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2818-2823) rheumatoid Arthritis - Animal Models II . . . . . . .

(#2824-2829) rheumatoid Arthritis - clinical Aspects VI: cardiovascular Disease in rheumatoid Arthritis . . . . . . . . . . . . . . .

(#2830-2835) Sytemic Lupus erythematosus clinical Aspects: Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2836-2841) Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment: clinical and Imaging Aspects of Axial Spondyloarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2902-2907) Systemic Sclerosis, Fibrosing Syndromes and raynaud’s – Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . .

28 b29 D

306 A Indigo e

Sapphire I

6 D 28 D 31 c

Indigo c

1.5 hrs.

9:00 –10:30 am

arHP sessions rheumatology Practice in the Age of the Affordable care Act

PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Update on orthotic Management for rheumatic Diseases through the Lifespan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Indigo D

202 A

1.5 hrs.

9:00 –10:30 am

arHP Concurrent abstract session (#2842-2847) education/community Programs . . . . . . . . . . . . . . . 32 A

1.5 hrs.

11:00 am –12:30 pm

aCr sessions 2013 Acr-eULAr Scleroderma classification Criteria PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PcMH-Model and the rheumatology Specialty . . . . . . . . . . .

6 A

Sapphire I

1.5 hrs.


30

11:00 am –12:30 pm

aCr Concurrent abstract sessions (#2848-2852) Fibromyalgia, Soft tissue Disorders and Pain: treatment and outcome Assessment . . . . . . . . . . . . . . . . . . . . . . . . .

(#2854-2859) orthopedics, Low back Pain, rehabilitation and Mechanisms of Pain in Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2860-2865) Pediatric rheumatology - Pathogenesis and Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2866-2871) rheumatoid Arthritis - clinical Aspects VII: remission, Flare and outcome Measures in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2872-2877) rheumatoid Arthritis - Pathogenetic Pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2878-2883) Sjögren’s Syndrome: clinical Advances . . . . . . . . .

(#2884-2889) Spondylarthropathies and Psoriatic Arthritis: clinical Aspects and treatment: Imaging in Axial Spondylarthropathies: challenges, Advances . . . . . . . . . . . . . . . . .

(#2890-2895) Systemic Lupus erythematosus - Animal Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(#2896-2901) Systemic Lupus erythematosus - clinical Aspects: cardiovascular and other complications of Lupus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

306 A

29 D

Sapphire A

6 D 31 c28 b

Indigo D

Indigo c

33 A

1.5 hrs.

11:00 am –12:30 pm

arHP session Highlights for the 2013 ArHP Annual Scientific Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

204 A

1.5 hrs.

11:00 am –12:30 pm

arHP Concurrent abstract sessions (#2908-2913) research and Health Services . . . . . . . . . . . . . . . . . . 32 A

1.5 hrs.

1:00 –4:00 pm

industry-supported Post meeting symposiaSee�program�book�page�353�for�the�list�of�symposia.


Meeting At-A-Glance WEDNESDAY, OCTOBER 30



31

Innovation Theater

these non-cMe accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhrMA code on Interactions with Healthcare Professionals.

all innovation theater presentations will be held in the exhibit Hall (Booth #731) at their designated time.

sunday, oCtoBer 27, 2013

10:30 - 11:15 am

CimZia© (certolizumab pegol) in rheumatologyPresented�by�UCB,�Inc.

12:30 - 1:15 pm

XelJanZ Path to discoveryPresented�by�Pfizer,�Inc.�

2:30 - 3:15 pm

application of Clinical trial data in rheumatoid arthritis: new insights from an established rheumatoid arthritis trialPresented�by�AbbVie

monday, oCtoBer 28, 2013

10:30 - 11:15 am

aCtemra (tocilizumab): Patient-focused treatment options in rheumatoid arthritisPresented�by�Genentech,�a�Member�of�the� Roche�Group

12:30 - 1:15 pm

Co-management of Patients with Psoriatic arthritis: a rheumatology-dermatology Cross-Clinical ProgramPresented�by�Amgen,�Inc.

2:30 - 3:15 pm

new insights into the Clinical utility of Vectra daPresented�by�Crescendo�Bioscience

tuesday, oCtoBer 29, 2013

10:30 - 11:15 am

targeting il-17 Pathways: a new Cytokine axis guiding future therapeutic options in Psoriatic arthritisPresented�by�Amgen,�Inc.

12:30 - 1:15 pm

simPoni® aria™ (golimumab) for the treatment of adult Patients with moderately to severely active rheumatoid arthritis (ra), in Combination with methotrexate (mtX): a fully Human, monoclonal antibody, anti-tnf infusion Presented�by�Janssen�Biotech,�Inc.

32


MAP convention center

Ground Level

1 Business Center

2 Exhibit HallDiscovery Center (Booth #1421)

– Career/Connections– Foundation Booth– Simple Tasks

Graffiti WallInnovation Theater (Booth #731)

3 Industry-Supported Symposia Information

4 Poster Hall

5 SessionSelect Lounge

6 Shuttle Buses

7 Visitor Information

8 Wi-Fi WayRecharge Area

14

3

2

5

6

8

7


33

convention center MAP

Mezzanine Level

1

1 Meet the Professor Session Rooms

34


ExhibitHall


Upper Level

1 ACR OfficeLost and Found

2 Foundation Donors’ Lounge

3 Late-breaking Abstracts

4 Newsroom

5 Nursing Mothers’ Room

6 Opening Lecture & Awards

7 Champagne Reception

8 Overflow Rooms

9 Prayer Room

10 RegistrationAttendee Lounge

– Graffiti Wall– Recharge Area

Clinical Trial/Registry Posters Concierge CenterHotel Reservations Membership BoothRibbon Distribution Technology Center

11 Speaker Ready Room

1

2

3

4

5

6

7

8

9

10

111

35

ExhibitHall


36

Exhibit HallList of Exhibitors

902 4S DAWN Clinical Software

1611 AbbVie

1142, 1147 Actelion Pharmaceuticals

2314 Alpinion Medical Systems

2413American College of Physicians/Annals of Internal Medicine

1300 Amgen, Inc.

2218 Antares Pharma

2414 APLAR

2616 Arthritis Foundation

1039 Arthritis Health Monitor TV

2412 Arthritis Introspecitve

2513 Arthritis National Research Foundation

2428 AstraZeneca

1348 Aushon BioSystems, Inc

1939 BioMed Central

1242 Bioventus, LLC

2212 Borgess Health

1017 Bristol-Myers Squibb

2518 British Society for Rheumatology

1932 California Rheumatology Alliance

2317

Canadian Institutes of Health Research – Institute of Musculoskeletal Health and Arthritis

1833 CarnaBio USA

1637 CEDARLANE

2019 Celgene Corporation

1009 Celltrion Healthcare Co., LTD.

2440 Center for Medicine in the Public Interest

2312 CESAS Medical

1229 Chugai Pharmaceutical Co., Ltd.

2712 Cleveland Clinic

1433 Clinical and Experimental Rheumatology

2214 Clinics of North Texas

2037 ContextMedia:Health’s Rheumatoid Health Network

1740 Corinthian Reference Laboratory

1639 CORRONA, Inc.

2219 Crescendo Bioscience, Inc.

1532 CuraScript SD

1136 DePuy Mitek

2436 DKBmed

1807 DynaMed/EBSCO

1241 eClinicalWorks

1516 Elsevier

1842 EMD Serono, Inc.

1338 Esaote North America

2515 ESCEO asbl

1839 Euroimmun US

2421 European League Against Rheumatism (EULAR)

2136 Everidis Health Sciences

1129 EXHIBITCHEK

2519Federation of Clinical Immunology Societies (FOCIS)

1514 Ferring Pharmaceuticals Inc.

901 Fidia Pharma USA

1633 Forest Pharmaceuticals, Inc.

2319 GE Healthcare

1037 Genalyte, Inc

1601 Genentech and Roche

1736 Genzyme, a Sanofi company

1247, 1341 GlaxoSmithKline

2119 Halozyme Therapeutics

1245 Happy Feet

2040 Hawaiian Moon

1413 Hologic

2239 Horizon Pharma, Inc.

1308 Hospira

2313 Hospital for Special Surgery

907 Immuno Concepts

2216 INC Research

BOOTH | EXHIBITOR




37

1035 Inova Diagnostics, Inc.

1030 inPractice Resources LLC

1040, 2713 Internet Center

2029 Janssen Biotech, Inc.

1415 Johns Hopkins Rheumatology

2718 Journal of Rheumatology, The

1801 La Lettre Du Rhumatologue - EDIMARK SANTE

2121 LabCorp

1004 Laclede Inc

2516 Letter to Editor Rheumatology

1729A, 1729b Lilly USA, LLC.

2215 LipoScience

1734 Lupus Initiative, The

2618 Mayo Clinic

1928 McKesson Specialty Health

1930 medac pharma, Inc.

900 Medimaps Group

2417 METEOR

1209 Metro Medical

2612

Mother to Baby conducted by Organization of Teratology Information Specialists

2720 National Data Bank for Rheumatic Diseases

1906 National Death Index

2512National Institute of Arthritis and Musculoskeletal and Skin Diseases

2615 National Scleroderma Core Centers

2443, 807 Networking Lounge

2113 New Balance Athletic Shoe, Inc.

2617 NOMID Alliance

2517 Northwestern University Division of Rheumatology

1737 Novartis Pharmaceuticals Corporation

1201 Novartis Pharmaceuticals Corporation

2418NYU Langone Medical Center - NYU Hospital for Joint Diseases

1000 Ochsner Health System

2514 OMERACT

1230 One Source Immunology

1228 Ossur Americas

2039 Oxford University Press

2419 PANLAR

2619 Patient Access Network Foundation

1835 PatientPoint®

1214 Pfizer, Inc.

1131 QIAGEN

2137 Quest Diagnostics

1437, 1645

Questcor Pharmaceuticals, Inc.

1143 Quidel Corporation

2714 R. J. Fasenmyer Center for Clinical Immunology

1029 RDL Reference Laboratory

2013 Regeneron Pharmaceuticals, Inc.

2236 Rheumatoid Patient Foundation

1512 Rheumatology News

2220 Rheumatology Practice News Special Edition

1829 Rottapharm Ltd

1904 RV Infusion Partners

2038 RX Biotech Specialty Pharmacy

1134 Sanofi Biosurgery

1239 Saretius

2437 Savient Pharmaceuticals

2716 Scandinavian Journal of Rheumatology

2621 Scleroderma Foundation

1006 SI-BONE

2521 Sjogren's Syndrome Foundation

1001 Sobi, Inc

1137 SonoSite

BOOTH | EXHIBITOR


convention center MAP




2520 Spondylitis Association of America

1941 Springer

2213 St. Peter's Hospital

814 Takeda Pharmaceuticals U.S.A., Inc.

1805 The Binding Site

2613 The Gout & Uric Acid Education Society

1536 The JAMA Network

2620 The Myositis Association

1028 TheraTest Laboratories, Inc.

1435 Thomson Reuters

1934 TSI Healthcare

2614Turkish Journal of Rheumatology

1813 UCB, Inc.

1038United Medical Instruments, Inc.

1232Value-Based Care in Rheumatology

2416 Vasculitis Foundation

2337 Vindico Medical Education

1900 VQ OrthoCare

2315 Wake Forest Baptist Health

1344 Warner Chilcott

1732 Wiley

1002 Zimmer

BOOTH | EXHIBITOR

38

KJob N

umber: 20116

Revision No: 1

Date: 8/6/13

051_36587P

g 1

Enbrel® (etanercept) Brief Summary

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

WARNINGSSERIOUS INFECTIONS AND MALIGNANCIES

Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Enbrel should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

• Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use.

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.

INDICATIONS AND USAGERheumatoid ArthritisEnbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone.

Polyarticular Juvenile Idiopathic ArthritisEnbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.

Psoriatic ArthritisEnbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone.

Ankylosing SpondylitisEnbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).

Plaque PsoriasisEnbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONSEnbrel should not be administered to patients with sepsis.

WARNINGS AND PRECAUTIONSSerious InfectionsPatients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.

Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.

Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions].

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel.

Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated.

TuberculosisCases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent

tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel.

Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Invasive Fungal InfectionsCases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel.

Neurologic EventsTreatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions].

MalignanciesLymphomasIn the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity.

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials.

LeukemiaCases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia.

During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.

Other MalignanciesInformation is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.

For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown.

Melanoma and Non-melanoma skin cancer (NMSC)Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept.

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years.

Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years.

Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel.

Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric PatientsMalignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.

In clinical trials of 696 patients representing 1282 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported.

Postmarketing UseIn global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported.

Patients With Heart FailureTwo clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully.

Hematologic EventsRare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities.

Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy.

Hepatitis B Virus ReactivationUse of TNF-blocking agents has been associated with reactivation of hepatitis B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.

Allergic ReactionsAllergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated.

Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe and the needle cover within the needle cap of the SureClick® autoinjector.

ImmunizationsLive vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions].

AutoimmunityTreatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.

ImmunosuppressionTNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions].

Use in Wegener’s Granulomatosis PatientsThe use of Enbrel in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions].

Use with Anakinra or AbataceptUse of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].

Use in Patients with Moderate to Severe Alcoholic HepatitisIn a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but

KJob N

umber: 20116

Revision No: 1

Date: 8/6/13

051_36587P

g 2

significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONSAcross clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions.

Clinical Studies ExperienceAdverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis

The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.

In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.

InfectionsInfections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents.

In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.

In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.

In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions].

Injection Site ReactionsIn placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.

ImmunogenicityPatients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel.

In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown.

The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading.

AutoantibodiesPatients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions].

Other Adverse ReactionsTable 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.

In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.

Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.

Adverse Reactions in Pediatric PatientsIn general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.

In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported older children.

Postmarketing ExperienceAdverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.

Adverse reactions are listed by body system below:

Blood and lymphatic pancytopenia, anemia, system disorders: leukopenia, neutropenia, thrombocytopenia, lymphadenopathy,

aplastic anemia [see Warnings and Precautions]

Cardiac disorders: congestive heart failure [see Warnings and Precautions]

Gastrointestinal disorders: inflammatory bowel disease (IBD)

General disorders: angioedema, chest pain

Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases

Immune disorders: macrophage activation syndrome, systemic vasculitis

Musculoskeletal and lupus-like syndrome connective tissue disorders:

Neoplasms benign, melanoma and non-melanoma skinmalignant, and unspecified: cancers, merkel cell carcinoma [see Warnings and Precautions]

Nervous system disorders: convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions]

Ocular disorders: uveitis, scleritis

Respiratory, thoracic interstitial lung disease and mediastinal disorders:

Skin and subcutaneous cutaneous lupus erythematous, cutaneoustissue disorders: vasculitis (including leukocytoclastic vasculitis),

erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar)

Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.

DRUG INTERACTIONSSpecific drug interaction studies have not been conducted with Enbrel.

VaccinesMost PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.

Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions].

Immune-Modulating Biologic ProductsIn a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L).

In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions].

CyclophosphamideThe use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions].

SulfasalazinePatients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown.

USE IN SPECIFIC POPULATIONSPregnancyPregnancy Category B. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Women who become pregnant during Enbrel treatment are encouraged to enroll in Amgen’s Pregnancy Surveillance Program. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.

Nursing MothersIt is not known whether Enbrel is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Enbrel, a decision should be made whether to discontinue nursing or to discontinue the drug.

Women who choose to continue Enbrel treatment while nursing are encouraged to enroll in Amgen’s Lactation Surveillance Program. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll.

Pediatric UseEnbrel is indicated for treatment of polyarticular JIA in patients ages 2 years and older [see Indications and Usage, Warnings and Precautions, Adverse Reactions].

Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied.

Rare (<0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions].

Geriatric UseA total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.

Use in DiabeticsThere have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials

Placebo Controlleda (Studies I, II, and a

Phase 2 Study)

Active Controlledb (Study III)

Placebo (N = 152)

Enbrelc (N = 349)

MTX (N = 217)

Enbrelc (N = 415)

Reaction Percent of Patients Percent of Patients

Infectiond (total)Upper Respiratory Infectionse

Non-upper Respiratory InfectionsInjection Site ReactionsDiarrheaRashPruritusPyrexiaUrticariaHypersensitivity

3930

15

11

921–1–

5038

21

37

8323––

8670

59

18

16195441

8165

54

43

16135221

a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.

bStudy duration of 2 years.cAny dose.dIncludes bacterial, viral, and fungal infections.e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza.

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials

(Studies I & II)

Placebo (N = 359)

Enbrela (N = 876)

Reaction Percent of Patients

Infectionb (total)Non-upper Respiratory InfectionsUpper Respiratory Infectionsc

Injection Site ReactionsDiarrheaRashPruritusUrticariaHypersensitivityPyrexia

2814

17

6

212––1

2712

17

15

31111–

a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses.

bIncludes bacterial, viral and fungal infections.c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis.

Rx Only.

This brief summary is based on ENBREL prescribing information v. 51: 06/2013

Manufactured by: Immunex Corporation

Thousand Oaks, CA 91320-1799US License Number 1132Marketed by Amgen Inc.

© 1998 – 2013 Immunex Corporation. All rights reserved.

US Patent Nos. 7,915,225; 5,605,690; Re. 36,755.

For more information please call 1-888-436-2735 or visit www.enbrel.com

© 2013 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. 60077-R3-V5

KJob N

umber: 20116

Revision No: 1

Date: 8/6/13

YM

C051_36587

Pg 3

IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONSPatients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown.Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.Pediatric PatientsIn patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.NEUROLOGIC EVENTSTreatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

CONGESTIVE HEART FAILURECases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.HEMATOLOGIC EVENTSRare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.HEPATITIS B VIRUS REACTIVATIONUse of TNF blockers, including ENBREL, has been associated with reactivation of hepatitis B virus (HBV) in chronic carriers of this virus. The majority of these reports occurred in patients on concomitant immunosuppressive agents, which may also contribute to HBV reactivation. Exercise caution when considering ENBREL in patients identified as carriers of HBV.ALLERGIC REACTIONSAllergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.IMMUNIZATIONSLive vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin.AUTOIMMUNITYAutoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.WEGENER’S GRANULOMATOSIS PATIENTSThe use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.MODERATE TO SEVERE ALCOHOLIC HEPATITISBased on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.ADVERSE EVENTSThe most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials.DRUG INTERACTIONSThe use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients.

Please see Brief Summary of Prescribing Information on preceding pages.

References: 1. Enbrel® (etanercept) Prescribing Information, June 2013. 2. Data on file, Amgen Inc. #1 Biologic for Rheumatologists, 2013. 3. Data on file, Amgen Inc. TEMPO CSR 57599 3 yr Clinical 06/2005.

75475-R1-V1

KJob N

umber: 20116

Revision No: 1

Date: 8/6/13

YM

C051_36587

Pg 4

Whether your patients are practicing their putt, spending time with family, or walking their dog, ENBREL has been a symbol of change for your patients with moderate to severe RA. Since 1998, ENBREL was the first and is still the only approved soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL is the #1 prescribed biologic by rheumatologists today.2†

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection.

Important Safety Considerations: ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis.

Please see Important Safety Information and Brief Summary for additional information.

* In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n = 228) and 1.8, 1.3, and 0.8 in the ENBREL + MTX arm (n = 231), respectively.3

HAQ-DI = Health Assessment Questionnaire-Disability Index† 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts.

In moderately to severely active rheumatoid arthritis (RA)

HELP PATIENTS GET BACK TO MANY OF THE ACTIVITIES THEY LOVE

A C T I V E • M O V E M E N T • E N A B L E • E X P L O R E • S U P P O R T • E N B R E L

ENBREL + MTX achieved significant improvements in physical function vs MTX alone as measured by HAQ-DI by Week 2 and out to Year 3.1*

Visit Booth #1300 to see how you can help patients get back to many of the activities they love.

Enbrel® and the Enbrel® logo are registered trademarks of Immunex Corporation.

2013 acr/arhp annual meeting session · manage your meeting your way with my annual meeting my...

Documents